Year All20262025202420232022202120202019201820172016201520142013 June 4, 2026 Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease Read more May 29, 2026 Arvinas to Present at Jefferies Global Healthcare Conference Read more May 18, 2026 Arvinas Employees Give Back During Company-wide Impact Day Read more May 12, 2026 Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update Read more May 12, 2026 Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) Read more May 5, 2026 Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 Read more May 1, 2026 Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer Read more March 18, 2026 Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days Read more March 11, 2026 Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders Read more February 24, 2026 Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Read more
June 4, 2026 Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease Read more
May 12, 2026 Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update Read more
May 12, 2026 Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) Read more
May 1, 2026 Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer Read more
March 18, 2026 Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days Read more
March 11, 2026 Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders Read more
February 24, 2026 Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Read more
